Shionogi Submits Rolling NDA for Ensitrelvir in US for COVID-19 Prophylaxis
Shionogi announced on April 1, 2025, the initiation of a rolling New Drug Application (NDA)...
Shionogi announced on April 1, 2025, the initiation of a rolling New Drug Application (NDA)...
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the conditional...
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that its Category 1 product,...
US pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced the commencement of the...
ANEXT, a Shanghai-based exosome specialist, has launched two clinical studies for their product ANEXT FIT...
Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that its...
Moderna Inc. (NASDAQ: MRNA), a leading mRNA specialist biotechnology company based in the U.S., has...
GlaxoSmithKline (GSK, NYSE: GSK) , a UK-based pharmaceutical giant, is poised to expand its partnership...
U.S. lawmakers have intensified their scrutiny of the FDA’s foreign inspection program, particularly for companies...
Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the...
Andon Health Co., Ltd (SHE: 002432), a healthcare company based in China, has announced that...
France’s Sanofi (NASDAQ: SNY) has announced a strategic partnership with protein-based vaccines specialist Novavax (NASDAQ:...
Andon Health Co., Ltd (SHE: 002432), a leading healthcare company based in China, has announced...
Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), a leading biotechnology company based in China, has...
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that the Committee for Medicinal Products for...
Yang Xiaoming, previously the chief engineer and chief scientist of China National Pharmaceutical Group Corporation...
China-based Walvax Biotechnology Co., Ltd (SHE: 300142) has announced positive results from a Phase III...
Gilead Sciences Inc. (NASDAQ: GILD) has reported a stagnant performance for the year 2023, with...
Gilead Sciences (NASDAQ: GILD) has reported a stagnant performance for 2023, with product sales remaining...
A wave of Chinese pharmaceutical companies has announced the receipt of Emergency Use Authorizations (EUAs)...